Literature DB >> 7911563

Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients.

S Duensing1, I Dallmann, J Grosse, J Buer, E Lopez Hänninen, M Deckert, S Störkel, H Kirchner, H Poliwoda, J Atzpodien.   

Abstract

We evaluated 28 patients with advanced renal cell carcinoma for the initial expression of P-glycoprotein (MDR1 gene product) employing immunocytochemistry. Tumor specimens were obtained upon primary tumor nephrectomy. In all patients, progression-free survival time following nephrectomy was evaluated and correlated statistically with the staining results. Progression-free survival of patients with no or very few (< 1%) P-glycoprotein-positive tumor cells (n = 8, median survival 27.0 months) was significantly extended (p < 0.04) as compared to patients with 1% or more P-glycoprotein-positive tumor cells (n = 20, median survival 4.0 months). Correlations with histopathological tumor characteristics were insignificant. These results suggest a potential role for P-glycoprotein as a biologic parameter predictive of tumor progression in renal cell carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911563     DOI: 10.1159/000227355

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.

Authors:  P Athanassiadou; P Athanassiades; E Petrakakou; C Zerva; M Mavrikakis
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.

Authors:  Y Soini; N Virkajärvi; H Raunio; P Pääkkö
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

3.  Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.

Authors:  Chiara Mignogna; Stefania Staibano; Vincenzo Altieri; Gaetano De Rosa; Giuseppe Pannone; Angela Santoro; Rosanna Zamparese; Massimino D'Armiento; Romualdo Rocchetti; Ernesto Mezza; Mario Nasti; Viviana Strazzullo; Vittorino Montanaro; Massimo Mascolo; Pantaleo Bufo
Journal:  BMC Cancer       Date:  2006-12-19       Impact factor: 4.430

4.  Capecitabine in the treatment of metastatic renal cell carcinoma.

Authors:  K Oevermann; J Buer; R Hoffmann; A Franzke; A Schrader; T Patzelt; H Kirchner; J Atzpodien
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

5.  Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.

Authors:  Rolf Warta; Dirk Theile; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Johanna Weiss; Gerhard Dyckhoff
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

6.  Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.

Authors:  S Hirata; O Katoh; T Oguri; H Watanabe; K Yajin
Journal:  Jpn J Cancer Res       Date:  2000-01

7.  Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1.

Authors:  Xingwang Zhu; Dongwei Xue; Jia Liu; Fengming Dong; Yongzhi Li; Yili Liu
Journal:  J Cancer       Date:  2021-02-02       Impact factor: 4.207

8.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.